Types of Opportunities we work with

Trophy Assets

Luxury Real Estate

Start-ups in Series A & B

EV

Healthcare

Other

Latest DON Opportunities

Foxrock Fintech

Foxrock develops Artificial Intelligence algorithms which trade the financial markets using machine learning models. Trading is typically 100% automated but in some cases human approval maybe required. The primary markets traded are US equities, Forex, precious metals and Indices. Trade execution is typically completed via software integrations with brokers such as Interactive Brokers and all of the software technology is proprietary, wholly owned and developed in house.

Radiatric

Radiatric was founded to develop and commercialize highly effective technologies that improve outcomes in patients with bacteremia, moderate to severe sepsis, and Septic shock. Sepsis is a life-threatening event that occurs in nearly a million people every year in the US alone and causes upwards of 200,000 deaths annually. Severe sepsis has a mortality rate of over 70%.

Telexos

Telexos develops products for the clinical cancer research market and for the personalized cancer diagnostics market. Focus of the developments is the detection and analysis of rare cells in blood, in particular circulating tumor cells (CTCs) and rare immune cells. Telexos started its laboratory in mid 2019. Circulating tumor cells (CTCs) can be detected in all solid tumors and are shed into the blood stream early on. CTCs have the advantage that the information (protein, RNA, DNA) of the different CTC-phenotypes are not mixed with others but are contained. Therefore, changes within the mixture of phenotypes during therapy can be easier detected. Since CTCs can be rare (e.g. 1 CTC in 10 billion blood cells) and quite heterogenous (reflecting the significant heterogeneity of the cells within a tumor of the same patient), it is mandatory to capture and analyze all available CTCs in a given blood sample. If not, important information in respect to determining the best available therapy and monitoring (and possibly adapting) the therapy in a personalized manner may be missed.

OmniSpirant Limited

OmniSpirant Limited was founded by Gerry McCauley in 2016. Gerry qualified as a Master of Pharmacy in 2001. Gerry has extensive commercial knowledge, industry contacts and has built an international network of experts in the fields of cell and gene therapy and respiratory drug delivery. Gerry is the inventor of OmniSpirant’s patent pending inhaled exosome technology. Since the company was founded a team of experienced industry leaders have joined the company’s management team. Our growing R&D team are at the forefront of innovation in the nascent field of exosome and extracellular vesicle research.

Orion Biotechnology

Orion Biotechnology is unlocking the therapeutic potential of previously undruggable G Protein-Coupled Receptors (GPCRs) with a novel drug modality, proven discovery platform and best-in-class molecules. The company is advancing a diversified pipeline of potential first-in-class/best-in-class antagonist and agonist therapies against high-value GPCR targets in oncology, immunology and other serious diseases. Orion is led by a highly experienced team with world leading expertise in GPCR pharmacology and peptide/protein engineering.

Quantumrock

Quantumrock is an AssetTech company differentiating through a patent-pending Artificial Intelligence Platform tapping unique alpha sources to create the highest quality, institutional-grade investment solutions in equities, volatility, fixed income, hard assets, factor investing and roboadvisor

Concarlo Therapuetics

Founded in July 2016 and headquartered in Brooklyn, New York, Concarlo is a precision-medicine oncology company focused on diagnosing and treating cancer with an innovative approach to targeting a unique cellular pathway – p27Kip1. Concarlo’s novel IpY therapeutic will be the first inhibitor to solve the CDK2 resistance issue, the first therapeutic to target p27 and the first to inhibit CDK4 and CDK2 simulataneously.

Bioxodes

Bioxodes is a clinical-stage biopharmaceutical company developing a first-in-class drug candidate, Ir-CPI, for the prevention of thrombosis and neuroinflammation in hemorrhagic stroke patients.

APR Technologies AB

APR Technologies AB is a Swedish high-tech company based in Enköping, Sweden. The acronym APR stands for Advanced Product Research. The company develops new technologies to improve performance of spacecrafts, electric vehicles, battery packs and demanding electronics. The core technology also has other suitable applications, for later exploitation. The company was founded in 2011, striving to bring a new technology to the world, able to improve energy efficiency in several applications. Miniaturized sensor systems and liquid pumping systems without moving parts have been developed and are stepwise being transformed into product families. To succeed on our journey, we aim to collaborate when possible. With suppliers and with clients as well as other potential partners for scaling up and reaching our targeted markets, globally. APR offer the next generation in electronics thermal management solutions. For spacecrafts it includes a game-changing device for thermal control, for electric vehicles and battery packs it enables battery modules with higher energy density & ultrafast charging, and for electronics it improves cooling without adding maintenance or losing reliability. The APR production system is implemented within its overall Quality Management System and is compliant to ECSS. APR personnel has in addition to heritage from APR products and developments, also vast experience from various prominent companies within space, telecom, and automotive hardware industry.

Amytrx Therapeutics

Amytrx is a clinical-stage biopharmaceutical company advancing the next generation of new anti-inflammatory peptide therapies for patients suffering from chronic inflammatory diseases. We are a group of dedicated scientific, medical, and business professionals all deeply committed to positively transforming the health and lives of patients.

Bar.On

Create any beer you like on the spot with Bar.on’s molecular beer mixing technology

Calciscon

At CALCISCON was founded in 2013 as a result of a breakthrough research in renal medicine by Dr. Andreas Pasch.
He investigated why the blood vessels of kidney patients calcify rapidly. This work led to the development of the T50, the first functional test for the assessment of Calcification Propensity. T50 identifies patients with high cardiovascular risk, and opens the possibility to slow down disease progression.

Avcon Jets

We are one of Europe’s major business aviation companies. We operate more than 80 aircraft worldwide and cover the whole spectrum of business jet models.

The Basketball Federation of Slovenia

Also known as KZS is the governing body of basketball in Slovenia.

InnoMedica

InnoMedica is a Swiss pharmaceutical company that uses an innovative nano-transport system to develop drugs that enable patients to make effective improvements in therapy. With its nanocarriers, InnoMedica pursues the goal of extending the circulation time of the transported active substances in the bloodstream and ensuring that the various active substances are only released precisely at the point of determination.

Liva Healthcare

On a stated mission to become a natural part of the healthcare system for people to prevent and overcome obesity, type 2 diabetes and cardiovascular diseases, Liva provides scalable, personalised health coaching.

Belassi

Everything Belassi does aims to set new standards for the Marine Hypercraft.

Droia Ventures

Droia Ventures is a specialist investor, dedicated to making an impact and save patient lives. We invest in the most promising life science companies.

DEUS Automobiles

DEUS Automobiles – established in Vienna, Austria, in 2020 – stands out in the increasingly competitive hypercar sector by offering its fresh and objective vision and innovative concepts in terms of luxury, performance, and exclusivity, and DEUS is poised to become a driving experience touchstone.

Bio Lift Sciences

LIfT Biosciences is preclinical UK & EU based Biotech developing an innate allogeneic first-in-class neutrophil based cell therapy platform called N-LIfT (Neutrophil based Leukocyte Infusion Therapy).

CardioMech

CardioMech is developing a catheter-based mitral valve repair technology designed to treat patients suffering from moderate to severe or severe, symptomatic DMR due to prolapse or flail.